Innovative Discoveries Series:Changing Epidemiology of Clostridium Difficile Infections: Making a Case for Preventive and Therapeutic Vaccines

Location: CCHS or web
Date: Fri: 06/22/18 12:00 PM - 1:00 PM

Innovative Discoveries Series - Changing Epidemiology of Clostridium Difficile Infections: Making a Case for Preventive and Therapeutic Vaccines

Location: CCHS or web
Date: Fri: 06/22/18 12:00 PM - 1:00 PM

Link: Watch online.

 

Changing Epidemiology of Clostridium Difficile Infections: Making a Case for Preventive and Therapeutic Vaccines

Michele Kutzler, Drexel University 
June 22, 2018 from 12:00-1:00 pm
Christiana Hospital Ammon Room 1100 or online at https://bluejeans.com/361095905

The Kutzler laboratory has developed a DNA-based vaccine encoding the toxins produced by the enteric pathogen, Clostridium difficile which is under US provisional patent (No. 61/506,973) and licensed by Inovio Pharmaceuticals.  Since the efficacy of the DNA toxin based vaccine should be determined in a model that closely represents the cohort most susceptible to C. difficile infection (CDI), the laboratory uses both preclinical aging mouse pathogenic CDI challenge models as well as human studies in a case controlled retrospective chart review and prospective clinical observational study at Hahnemann University Hospital.  Collecting patient associated risk factors for acquisition of clostridium difficile infections will inform development of a clinical prediction tool for acquisition of CDI, severity and recurrence and help in the design of future C. diff vaccine trials. The learning objectives of this lecture are to (1) learn about the current epidemiology of Clostridium difficile infection; (2) review the pathogenesis of Clostridium difficile infection mediated by two enterotoxins, A and B; (3) summarize the required host immune responses necessary for successful defense against infection and recurrence of disease; (4) to summarize the clinical pipeline of C. difficile vaccines and to show our design and preclinical efficacy testing of a DNA-based vaccine encoding the toxins A and B of Clostridium difficile;  and to (5) summarize the clinical research study taking place at Hahnemann University Hospital designed to identify patient specific risk factors for CDI in adults. 

For more information and to RSVP, click here. 



Location:
CCHS or web
Date:
Fri: 06/22/18 12:00 PM - 1:00 PM
Registration Deadline:
06/22/18

Continuing Ed Credits: 1

Contact:
Deena Chisholm
phone:
302-733-5868


register